Skip to main content
Premium Trial:

Request an Annual Quote

Shares in Third Wave Tumble 5.9 Percent

This article incorrectly reported that Piper Jaffray downgraded Third Wave's shares today. In fact, Piper downgraded the stock on March 1, not April 1.

NEW YORK, April 1 (GenomeWeb News) - Shares in Third Wave Technoloigies were down 5.9 percent, or $.34, at $5.42 in mid-afternoon trading.

 

As GenomeWeb News  reported, Third Wave in February reported a 16.5-percent drop in fourth-quarter revenue and almost tripled losses for the fourth quarter of 2004.

 

The company had $8.1 million in revenues, down from $9.7 million during the same quarter in 2003. Third Wave said that more than half, or $4.7 million, of total revenues were derived from clinical molecular diagnostics, meaning that this business segment grew almost 90 percent compared to the fourth quarter of 2003.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.